This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
March 2001. These samples were used to estimate the distribution of doses received in the aggregate population at the specified dates. No further details were given. The sample sizes were not reported. If the randomisation was adequately performed and the sample sizes large enough, the samples should have been representative of the study population.
Study design
This was an observational study carried out in 3 sites. Dallas and Houston each conducted one of the study publicity campaigns. Washington DC conducted neither of them, although it was not stated whether or not there was a campaign of any kind. Random samples were taken pre-and post-publicity campaigns to estimate the number of hepatitis B doses received by the study population. Pre-and post-intervention hepatitis B coverage was ascertained by conducting computer assisted telephone interviews.
Analysis of effectiveness
The primary health outcomes used in the analysis were the uptake of doses of the hepatitis B vaccination, the uptake of the hepatitis B third dose and the number of children rendered seroprotected. The demographics of the cities were not compared in this paper. See details of the original clinical paper in "Other Publications of Related Interest".
Effectiveness results
The effectiveness results were as follows:
At the end of the intervention the number of children receiving any dose increased by 865 (from 1,953 (22.5%) to 2,818 (32.4%)) in the media group and by 437 (from 1,181 (20.9%) to 1,618 (28.6%)) in the community mobilisation group.
At the end of the intervention the number of children who had completed the series of 3 doses increased by 1,176 (13.5%)(from 1,238 to 2,414) in the media group and by 390 (6.9%)(from 801 to 1,191) in the community mobilisation group. The increase in the control site, Washington DC, was 0.
During the intervention it is estimated that 3,116 doses of HepB were administered to children in the media group and 1,243 doses to the community mobilisation group.
With the assumption that seroprotection was 95%, 85% and 50% for doses 3, 2 and 1, the estimated number of additional immune children was 926 (10.7%) by media intervention and 403 (7.1%) by community mobilisation.
Clinical conclusions
Although the increases in the number of children who completed three doses were modest for both Houston and Dallas areas, both media and community mobilisation proved to be effective methods of increasing the uptake. When the two methods were compared, the children in the media intervention group took more doses.
